Nicolas D et al.2015. Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4. Expert Rev Anti Infect Ther 13: 947–963.
Proietti FA , Carneiro-Proietti AB , Catalan-Soares BC , Murphy EL , 2005. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24: 6058–6068.
Marinho J , Galvao-Castro B , Rodrigues LC , Barreto ML , 2005. Increased risk of tuberculosis with human T-lymphotropic virus-1 infection: a case–control study. J Acquir Immune Defic Syndr 40: 625–628.
de Lourdes Bastos M et al.2009. Prevalence of human T-cell lymphotropic virus type 1 infection in hospitalized patients with tuberculosis. Int J Tuberc Lung Dis 13: 1519–1523.
Norrgren HR et al.2008. Increased prevalence of HTLV-1 in patients with pulmonary tuberculosis coinfected with HIV, but not in HIV-negative patients with tuberculosis. J Acquir Immune Defic Syndr 48: 607–610.
Verdonck K et al.2007. HTLV-1 infection is frequent among out-patients with pulmonary tuberculosis in northern Lima, Peru. Int J Tuberc Lung Dis 11: 1066–1072.
Verdonck K , Gonzalez E , Schrooten W , Vanham G , Gotuzzo E , 2008. HTLV-1 infection is associated with a history of active tuberculosis among family members of HTLV-1-infected patients in Peru. Epidemiol Infect 136: 1076–1083.
Seaton RA , 1997. Tuberculosis and human T-cell lymphotropic virus type 1 infection. https://doi.org/10.1093/clinids/24.5.1026.
Grassi MF et al.2016. Tuberculosis incidence in a cohort of individuals infected with human T-lymphotropic virus type 1 (HTLV-1) in Salvador, Brazil. BMC Infect Dis 16: 491.
Gessain A , Cassar O , 2012. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 3: 388.
Eshima N et al.2009. Age and gender specific prevalence of HTLV-1. J Clin Virol 45: 135–138.
Allain JP et al.1992. Antibody to HIV-1, HTLV-I, and HCV in three populations of rural Haitians. J Acquir Immune Defic Syndr 5: 1230–1236.
Schierhout G et al.2020. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis 20: 133–143.
Journo C , Mahieux R , 2011. HTLV-1 and innate immunity. Viruses 3: 1374–1394.
Carvalho NB et al.2018. Impaired TNF, IL-1β, and IL-17 production and increased susceptibility to Mycobacterium tuberculosis infection in HTLV-1 infected individuals. Tuberculosis (Edinb) 108: 35–40.
Sia JK , Rengarajan J , 2019. Immunology of Mycobacterium tuberculosis infections. Microbiol Spectr 7: 10.
Kohno T et al.2005. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci 96: 527–533.
Jasenosky LD , Scriba TJ , Hanekom WA , Goldfeld AE , 2015. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev 264: 74–87.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||60||45||1|
This retrospective case–control study examined the prevalence of HTLV-I and its association with tuberculosis among urban clinic patients in Haiti. Prevalence of HTLV-I among tuberculosis cases was 2.1% and among controls was 2.4%. Prevalence of HLTV-I was higher in females than males (odds ratio [OR] 2.45, P = 0.020). HTLV-I prevalence in those ≥ 50 years was 8.4% compared with 1.3% in those < 50 (OR 6.74, P < 0.001). We found no association between HTLV-I and tuberculosis in this population.
Financial support: This work was supported by the National Institutes of Health grants K23-AI131913 (to K. M. D.), and U19-AI111143.
Authors’ addresses: Kathleen F. Walsh, Myung Hee Lee, Josef A. Brejt, Mary J. Reust, and Kathryn Dupnik, Weill Cornell Medicine, New York, NY, E-mails: firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, and firstname.lastname@example.org. Marc Jean Juste, Genevieve Hilaire and Jean William Pape, GHESKIO Centers, Port-au-Prince, Haiti, E-mails: email@example.com, firstname.lastname@example.org, and email@example.com. Serena Koenig, Brigham and Women’s Hospital, Boston, MA, E-mail: firstname.lastname@example.org.